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Abstract
Introduction: Mucosa associated lymphoid tissue lymphomas are the most common lymphomas of the salivary
glands. The benign lymphoepithelial lesion is also a lymphoproliferative disease that develops in the parotid gland.
In the present case report, we describe one case of benign lymphoepithelial lesion with a subsequent low
transformation to grade mucosa associated lymphoid tissue lymphoma appearing as a cystic mass in the parotid
gland.
Case presentation: A 78-year-old Caucasian female smoker was referred to our clinic with a non-tender left facial
swelling that had been present for approximately three years. The patient underwent resection of the left parotid
gland with preservation of the left facial nerve through a preauricular incision. The pathology report was consistent
with a low-grade marginal-zone B-cell non-Hodgkin lymphoma (mucosa associated lymphoid tissue lymphoma)
following benign lymphoepithelial lesion of the gland.
Conclusions: Salivary gland mucosa associated lymphoid tissue lymphoma should be considered in the differential
diagnosis of cystic or bilateral salivary gland lesions. Parotidectomy is recommended in order to treat the tumor
and to ensure histological diagnosis for further follow-up planning. Radiotherapy and chemotherapy should be
considered in association with surgery in disseminated forms or after removal.
Introduction
Mucosa associated lymphoid tissue (MALT) lymphomas
are non-encapsulated clusters of lymphocytes found
throughout the mucosal tissues of the aero-digestive
tract. The non-Hodgkin type lymphomas that arise from
these lymphocyte aggregates (MALT lymphoma) are of
B-cell lineage, the commonest involving the salivary
glands [1]. A MALT lymphoma has been presumed to
be associated with autoimmune or inflammatory dis-
eases [2]. The benign lymphoepithelial lesion (BLL) is
also a lymphoproliferative disease that develops in the
parotid gland. Although, BLL is a benign disease, subse-
quent malignancies have also been reported [3,4].
The lymphoma arising from MALT was first described
by Isaacson and Wright in 1983 [5]. MALT lymphoma
arising from salivary glands is a rare entity; available
data in the literature are scarce, confined to small series
and isolated case reports. The characteristics and clinical
outcome of this unusual presentation are largely
unknown [6]. Early diagnosis relies on a high index of
suspicion.
In the present case report, we describe one case of
BLL with a subsequent low transformation to grade
MALT lymphoma appearing as a cystic mass in the par-
otid gland.
Case Presentation
A 78-year-old Caucasian female smoker was referred to
our clinic with a non-tender left facial swelling that had
been present for approximately three years. The patient
was otherwise asymptomatic. She had no history of
malignancy or autoimmune diseases. A firm mobile
mass was present in the left parotid gland.
Examination revealed a 5 cm firm mobile mass in the
superficial lobe of the left parotid. The left facial nerve
was intact (House-Brackmann scale Grade I). No other
abnormalities were found in the nasopharynx, oral cav-
ity, larynx or ears. There was no pathological enlarge-
ment of the cervical lymph nodes. Laboratory tests were
within normal limits. Hepatitis B virus (HBV) and hepa-
titis C virus (HCV) serologies were negative.
The patient had undergone ultrasonography-guided
fine needle aspiration of the left parotid gland several
months before. The cytological examination revealed
mononuclear and inflammatory cells and a diagnosis of
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antibiotics but with little effect. Unfortunately, the mass
on the left parotid continued to enlarge. After admission
to our clinic, a helical CT scan was performed which
revealed a solid mass with an irregular surface in the
left parotid gland (Figure 1).
The patient underwent resection of the left parotid
gland with preservation of the left facial nerve through a
preauricular incision (Figure 2). Identification of the
branches of the facial nerve was made by using loupes
magnification and with intraoperative electric stimula-
tion of the identified branches of the facial nerve. The
size of the resected tumor was 5 × 7 cm (Figure 3). The
surgical specimen was sent for a histopathological
examination.
The pathology report was consistent with a low-grade
marginal-zone B-cell non-Hodgkin lymphoma (MALT
lymphoma) following BLL of the gland. According to
the report, there was infiltration of the normal salivary
tissue by a heterogenous mixture of lymphocytes and
isolated blastic cells.
Postoperative recovery was uneventful and facial nerve
function was intact. CT scan of the head, neck, chest
and abdomen at two and six months after the surgery
revealed no evidence of lymphoma infiltration. Our
patient had isolated surgical treatment without che-
motherapy. By the time this report was completed, the
patient had been followed for 13 months without evi-
dence of recurrence.
Discussion
Primary lymphomas of the salivary glands are rare and
account for 4.7% of lymphomas at all sites [7]. A non-
Hodgkin lymphoma of a salivary gland may appear as a
painless, progressively enlarging mass [8-11]. Therefore,
it is rarely suspected before biopsies or surgical removal.
MALT lymphomas developing within the salivary glands
may be related to chronic lymphoid hyperplasia.
The native absence of MALT within the salivary
glands necessitates the development of acquired MALT
from underlying lymphoid stimulation and infiltration
before MALT lymphoma can develop [12]. Low-grade
MALT lymphomas of the parotid gland usually arise in
a setting of BLL [13]. The main histological characteris-
tic of BLL of the parotid gland is the presence of clus-
tered B cells inter-digitating with ductal epithelial cells.
According to Amft et al [14], BLL can be considered a
‘premalignant lesion’ due to the fact that it can contain
clonal populations of B cells, although it is generally
regarded as a benign lesion. The transformation from
BLL to MALT lymphoma is believed to be a multi-step
Figure 1 Preoperative CT scan of the tumor of the left parotid
gland.
Figure 2 Preoperative planning of the preauricular incision -
the circular dotted line represents the tumors margins.
Figure 3 The surgical specimen.
Konofaos et al. Journal of Medical Case Reports 2011, 5:380
http://www.jmedicalcasereports.com/content/5/1/380
Page 2 of 5process. The initial event of this process may be a long-
term stimulation of activating B cells by an inflamma-
tory stimulus [15]. Hiltbrand et al [16] also suggested
that MALT lymphomas arise from BLL, not from intra-
parotid lymphoid aggregates.
Association between MALT lymphoma and autoim-
mune diseases such as systemic lupus erythematous
[17,18] or inflammatory diseases such as Helicobacter
pylori infection in the stomach has been discussed. In
the present case, no gastric lesions were observed after
stomach examination. According to Rosenstiel et al [19]
in patients with Sjögren’s syndrome, the risk of develop-
ing Non-Hodgkin’s lymphoma increases 44-fold and
80% of these lymphomas are of the MALT type. Our
patient had no clinical evidence of Sjögren’s syndrome.
According to Anacak et al [6] salivary gland MALT
lymphoma is mainly a disease affecting women; in their
study the ratio of females to males was 3/1. Kojima et al
[20] reported a female-to-male ratio of 1.7/1.0 for pri-
mary lymphomas of the salivary glands. Kalpadakis et al
[21] reported a series of 76 patients with non-gastric
extra-nodal marginal zone lymphomas in which two
thirds of the patients were female. The reason for this
female predominance is not clear.
Radiological representation of MALT lymphomas of
the parotid gland is scarce [22]. According to Corr et al
[23] who presented a cohort of 10 HIV-infected children
with MALT lymphomas of the parotid gland, the CT
scan appearance of these lesions consisted of multiple
hypoechoic solid nodules, which corresponded to hyper-
plastic lymphoid tissue or lymphoma. Cystic lesions
(from compression of terminal parotid ducts by contigu-
ous hyperplastic or neoplastic lymphoid tissue) and
punctuate calcification, both intracystic and parenchy-
mal may coexist. This radiologic appearance has also
been described in BLL encountered in patients with
AIDS [24] or Sjögren’s syndrome [25].
Currently, there is controversy in the reported litera-
ture regarding the accuracy of PET-CT scan in MALT
lymphomas. Elstrom et al [26] evaluated the accuracy of
PET-FDG in identifying various lymphomas subtypes.
According to their results, PET-FDG detected 67% of
marginal zone lymphoma. Hoffmann et al [27] reported
increased FDG uptake in patients with nodal marginal
zone lymphoma but not in those with extranodal dis-
ease, suggesting that the FDG-avidity depends on tumor
location and ⁄or the lymphoma subtype. Perry et al [28]
suggested that PET -CT is a useful tool for both, initial
staging and follow-up after treatment in patients with
MALT lymphoma and its sensitivity depends on disease
location and stage at initial diagnosis.
Most non-gastric MALT lymphomas have been noted
to be indolent. Disseminated disease is relatively slow to
develop in affected patients. Up to 50% of the patients
w i t hn o n - g a s t r i cM A L Tl y m p h o m ah a v em u l t i p l e
involved sites [29]. Whether this phenomenon can be
attributed to synchronous disease occurrence at multiple
sites or to undetected sub-clinical disease, the mechan-
ism of disease dissemination is unknown [30].
An association between hepatitis C virus (HCV) infec-
tion and B-cell lymphomas has previously been
reported, especially in countries in which the prevalence
of HCV is relatively high [31,32]. Other researchers have
not found this association [33,34]. Thus, further studies
are needed to define the role of HCV infection in the
pathogenesis of MALT lymphoma. Rosenstiel et al [19]
suggested that any patient with a cystic parotid mass
must be screened for HIV infection or for Sjogren dis-
ease, because it is more likely that the cystic mass is
derived from either one of these underlying diseases
than to a MALT lymphoma. According to Klussmann et
al [35] Epstein - Barr virus (EBV), Human herpetovirus
(HHV) types -6 and -8, HCV and HIV infections have
been involved in the etiology of salivary MALT
lymphomas.
In our practice, clinical examination, preoperative
FNA of the suspicious lesion and radiological investiga-
tion in certain cases, is part of the preoperative assess-
ment of a suspicious parotid gland lesion. However,
Ando et al [36] suggested that a parotid MALT lym-
p h o m ai sh a r dt od i a g n o s eb yf i n e - n e e d l ea s p i r a t i o n
cytology.
T h i e b l e m o n te ta l[ 3 7 ]s u g g e s t e dt h a tp a t i e n t sw i t h
localized disease generally were treated with surgery or
radiotherapy. Surgery is strongly recommended as a
diagnostic tool of malignant lymphoma of the parotid
gland [38], since histological evaluation is essential for
treatment of malignant lymphoma. Parotid surgery is
positively recommended both in order to treat the
tumor and to ensure histological diagnosis of the tumor
for further follow-up planning. The prognosis is excel-
lent for patients with MALT lymphoma of the parotid
gland. Limited data indicate five-year survival rates of
more than 80%.
Once MALT lymphoma is diagnosed, an in-depth eva-
luation for synchronous multi-sited involvement and
disseminated disease should be undertaken before initia-
tion of local therapy. Radiotherapy and chemotherapy
should be considered in association with surgery in dis-
seminated forms or after removal. Sarris et al suggested
[38] irradiation in case of localized lesions in early stage
and chemotherapy in those with advanced disease. Mar-
ioni et al [15] suggested that radiotherapy and che-
motherapy should be considered in association with
surgery in disseminated forms or after incomplete
removal. Isobe et al [39] treated 37 patients with Stage
IE extragastric MALT lymphomas with radiotherapy
only. Local control was obtained in 97.3% of the
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reported as 91.9%. As far as chemotherapy in patients
with MALT-type lymphoma is concerned, although
there is limited experience [40], clinical trials of systemic
therapies are strongly advised.
Regional and distant relapses are not common in gas-
tric MALT lymphomas, but extragastric MALT lympho-
mas tend to be more aggressive and may recur in the
regional or distant lymph nodes and in other organs
[30,41]. According to Wenzel et al, patients with
MALT-lymphoma of the head and neck are at a rela-
tively high risk for early dissemination and subsequent
distant recurrence when only local therapies are applied.
In the current case, there was no lymph node or other
organ involvement.
Conclusion
Salivary gland MALT lymphoma should be considered
in the differential diagnosis of cystic or bilateral salivary
gland lesions. After histopathological confirmation of a
suspicious parotid gland lesion as a parotid gland
MALT lymphoma, careful follow-up is needed with
attention either to the remaining parotid gland or to
other major salivary glands and organs in the head and
neck region.
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